The FDA granted accelerated approval to polatuzumab vedotin-piiq (Polivy, Genentech) in combination with bendamustine and a rituximab product (BR) to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.